# A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Clinical trial · Eli Lilly and Company

- Archive id: nct:NCT05872620
- Published: 2023-05-24
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05872620
- Source URL: https://clinicaltrials.gov/study/NCT05872620
- Provenance: clinicaltrials

## Abstract

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: ATTAIN-2
- status: COMPLETED
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 1613
- sponsor: Eli Lilly and Company
- conditions: Obesity; Overweight; Type 2 Diabetes
- interventions: DRUG: Orforglipron; DRUG: Placebo
- start date: 2023-06-05
- start date type: ACTUAL
- primary completion date: 2025-08-08
- has results: true
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

Cited in dossiers:
- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.